

Stimunity Raises Additional Capital to Secure its Path to the Clinic

Paris, May 2020 – Stimunity, the Paris-based cancer immunotherapy company focused on STING, is pleased to announce an additional capital increase of €900k from Portage Biotech, Inc. This new raise comes along with new preclinical data showing efficacy of the cGAMP-VLP with systemic route of administration and reinforcing the existing package of preclinical data.

The STING pathway is a breakthrough way to activate innate immunity with potential in treating oncology, infectious diseases and other diseases. However, it also comes with challenges as this pathway is expressed by most cell types. As a result, STING activation leads to a different mechanism of action depending on which cell type receives the stimulation. In this context, intratumoral administration of compounds that activate STING may not be the optimal way of augmenting an anti-tumor response. Alternatives that utilize a systemic route of administration have been studied and could be superior to intratumorally administration, especially for tumors not accessible locally.

“We knew since the beginning of our company that STING-activating cGAMP Virus-Like Particle (cGAMP-VLP) technology has a unique property enabling its payload to preferentially target immune cells, which is different from other chemical STING approaches. This has an impact on the stimulation of the immune system and the quality of the anti-tumoral response. We have determined that this targeting mechanism is able to deliver the cGAMP via systemic route of administration and that it leads to induction of systemic anti-tumor T-cell response” says Nicolas Manel, co-founder and Scientific Advisor of the company.

These new preclinical results provide additional momentum to Stimunity’s cGAMP-VLP approach and reinforces the advantage of using cGAMP-VLP to target STING. “We are very happy about this new result, and we are refining our clinical trial strategy to take advantage of the new delivery route” says Sylvain Carlioz, CEO.

About Portage Biotech



Portage is a unique entity in the world of biotechnology, enabling research and development to produce more clinical programs and maximize potential returns by eliminating typical overhead costs associated with many biotechnology companies. We nurture the creation of early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by providing funding, strategic business and clinical counsel, and shared services, to enable efficient, turnkey execution of

commercially-informed development plans. The portfolio encompasses nine subsidiary companies whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. In collaboration with our subsidiaries, we create viable product development strategies, to cost-effectively deliver best-in-class R&D, clinical trial design, and financial and project management, to ultimately build value and support commercial potential.

For more information, visit <http://www.portagebiotech.com>.

About Stimunity



Stimunity is an early-stage research and development company focused on the development of STING agonists in cancer. The technology, licensed from Institut Curie, Inserm, and University of Oxford, is based on a unique biologic approach which combines the endogenous STING activator encapsulated into a Virus-Like Particle (VLP). Stimunity's drug is best-in-class, and activates the innate immune system, enhances T-cell response against tumor cells.

More information at <https://stimunity.com> or contact@stimunity.com.